SSA
EVGN icon

Schonfeld Strategic Advisors’s Evogene EVGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,940
Closed -$25K – 2651
2022
Q1 		$25K Buy
+1,940
New +$26.2K ﹤0.01% 2383

Other funds holding EVGN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

Schonfeld Strategic Advisors's EVGN Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of Evogene (EVGN) in Q2 2022, closing a stake of 1,940 shares — an estimated $25K sold.

Schonfeld Strategic Advisors first reported a position in EVGN in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 29 funds tracked by Wall St. Rank hold EVGN as of Q2 2022.

  • Schonfeld Strategic Advisors reported no remaining Evogene position as of Q2 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,940 Evogene shares in Q2 2022, an estimated $25K.
  • Schonfeld Strategic Advisors first reported a position in Evogene in Q1 2022 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Evogene position peaked at $25K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Evogene as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.